Mesirow Financial Investment Management Inc. Raises Stake in Vaxart, Inc. (NASDAQ:VXRT)

Mesirow Financial Investment Management Inc. increased its holdings in Vaxart, Inc. (NASDAQ:VXRT) by 100.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 40,000 shares of the biotechnology company’s stock after buying an additional 20,000 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Vaxart were worth $34,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of VXRT. RA Capital Management L.P. acquired a new position in shares of Vaxart in the 1st quarter valued at about $20,000,000. Vanguard Group Inc. raised its position in Vaxart by 19.9% during the first quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock valued at $10,984,000 after acquiring an additional 1,404,391 shares in the last quarter. Millennium Management LLC raised its position in Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Vaxart in the second quarter valued at approximately $402,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in Vaxart in the 2nd quarter worth approximately $65,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Oppenheimer started coverage on shares of Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 target price for the company.

Vaxart Stock Down 1.1 %

VXRT stock opened at $0.71 on Thursday. Vaxart, Inc. has a 52-week low of $0.52 and a 52-week high of $1.54. The firm has a market cap of $126.74 million, a P/E ratio of -1.55 and a beta of 0.70. The company’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $0.77.

Vaxart Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.